Hosted on MSN

Beacon trial data makes Beam Therapeutics (BEAM) an attractive buy

Beam Therapeutics (NASDAQ:BEAM) is one of the most promising mid-cap healthcare stocks under $50. On December 9, H.C. Wainwright analyst Patrick Trucchio reaffirmed his bullish stance on Beam ...
Nasdaq

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...
Nasdaq

Beam Therapeutics Reports Enrollment of Over 40 Patients in BEACON Trial for Sickle Cell Disease; Anticipates Key Milestones in 2025

Beam Therapeutics has announced significant progress in its clinical trials and portfolio regarding precision genetic medicines, particularly in the area of sickle cell disease (SCD). Over 40 adult ...
Seeking Alpha

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

SAN DIEGO, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (BEAM) (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new ...
NBC4 Columbus

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology ...

CAMBRIDGE, Mass., June 13, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, announces new safety and ...